Expressional difference of RHEB, HDAC1, and WEE1 Proteins in the stromal tumors of the breast and their significance in tumorigenesis

Korean Journal of Pathology

Volumn 46, Issue 4, 2012, Pages 324-330

  Eom, Minseob ^a   Han, Airi ^a   Lee, Mi Jeong ^a   Park, Kwang Hwa ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Breast neoplasms; HDAC1 protein; RHEB protein; Stromal cells; WEE1 protein

Indexed keywords

EID: 84867880636     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2012.46.4.324     Document Type: Article

References (30)

1. Rosen PP. Rosen's breast pathology. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2009; 187-229.
2. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran's pathologic basis of disease. 8th ed. Philadelphia: Saunders, 2010; 1091-2.
3. Parker SJ, Harries SA. Phyllodes tumours. Postgrad Med J 2001; 77: 428-35.
4. Eom M, Han A, Yi SY, Shin JJ, Cui Y, Park KH. RHEB expression in fibroadenomas of the breast. Pathol Int 2008; 58: 226-32.
5. Aspuria PJ, Tamanoi F. The Rheb family of GTP-binding proteins. Cell Signal 2004; 16: 1105-12.
6. Li Y, Corradetti MN, Inoki K, Guan KL. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 2004; 29: 32-8.
7. Zhang Z, Yamashita H, Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat 2005; 94: 11-6.
8. Kawai H, Li H, Avraham S, Jiang S, Avraham HK. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 2003; 107: 353-8.
9. Park SY, Jun JA, Jeong KJ, et al. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 2011; 25: 1677-81.
10. Patani N, Jiang WG, Newbold RF, Mokbel K. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res 2011; 31: 4115-25.
11. Backert S, Gelos M, Kobalz U, et al. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int J Cancer 1999; 82: 868-74.
12. Ried T, Just KE, Holtgreve-Grez H, et al. Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res 1995; 55: 5415-23.
13. Park KH, Choi SE, Eom M, Kang Y. Downregulation of the anaphase-promoting complex (APC)7 in invasive ductal carcinomas of the breast and its clinicopathologic relationships. Breast Cancer Res 2005; 7: R238-47.
14. Sawhney N, Garrahan N, Douglas-Jones AG, Williams ED. Epithelial-stromal interactions in tumors: a morphologic study of fibroepithelial tumors of the breast. Cancer 1992; 70: 2115-20.
15. Yamashita J, Ogawa M, Egami H, et al. Abundant expression of immunoreactive endothelin 1 in mammary phyllodes tumor: possible paracrine role of endothelin 1 in the growth of stromal cells in phyllodes tumor. Cancer Res 1992; 52: 4046-9.
16. Gómez MR, Sampson JR, Whittemore VH. Tuberous sclerosis complex: developmental perspectives in psychiatry. 3rd ed. New York: Oxford University Press, 1999.
17. Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem 1997; 272: 10608-15.
18. Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci 2001; 58: 1636-49.
19. Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 2003; 278: 32493-6.
20. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 2003; 63: 5656-68.
21. Mavrakis KJ, Zhu H, Silva RL, et al. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev 2008; 22: 2178-88.
22. Zheng H, Liu A, Liu B, Li M, Yu H, Luo X. Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. Cancer Lett 2010; 297: 117-25.
23. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974-84.
24. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998; 51: 227-38.
25. Zhang Z, Yamashita H, Toyama T, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004; 10: 6962-8.
26. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001; 58: 1907-22.
27. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004; 15: 252-6.
28. Yan Y, Spieker RS, Kim M, Stoeger SM, Cowan KH. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. Oncogene 2005; 24: 3285-96.
29. Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 2010; 122: 347-57.
30. Stathis A, Oza A. Targeting Wee1-like protein kinase to treat cancer. Drug News Perspect 2010; 23: 425-9.